Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer

Current treatments for castration-resistant prostate cancer (CPRC) that target androgen receptor (AR) signaling improve patient survival, yet ultimately fail. Here we provide novel insights into treatment response for the anti-androgen abiraterone by analyses of a genetically-engineered mouse model...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Zou, Min, Toivanen, Roxanne, Mitrofanova, Antonina, Floch, Nicolas, Hayati, Sheida, Sun, Yanping, Le Magnen, Clémentine, Chester, Daniel, Mostaghel, Elahe A., Califano, Andrea, Rubin, Mark A., Shen, Michael M., Abate-Shen, Cory
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5501744/
https://ncbi.nlm.nih.gov/pubmed/28411207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1174
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados